-
公开(公告)号：US20240228603A1
公开(公告)日：2024-07-11
申请号：US18400894
申请日：2023-12-29
发明人： Nancy Elizabeth STAGLIANO , James William WEST , Kathryn KAMATH , Paul Henry BESSETTE , Fred GLUCK , Jason Gary SAGERT , Patrick DAUGHERTY
IPC分类号： C07K16/22 , A61K39/00 , A61K39/395 , A61K47/68 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/30 , G01N33/68
CPC分类号： C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , G01N33/6845 , G01N33/6854 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50
摘要： The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
-
2.发明公开公开(公告)号：US20240084010A1
公开(公告)日：2024-03-14
申请号：US18472748
申请日：2023-09-22
发明人： Bryan Allen IRVING , Sherry Lynn LA PORTE , Jason Gary SAGERT , Daniel Robert HOSTETTER , Olivia Jennifer RAZO , Clayton William WHITE , Jennifer Hope RICHARDSON
IPC分类号： C07K16/28 , A61K39/395 , A61K47/68 , C07K16/30
CPC分类号： C07K16/2809 , A61K39/395 , A61K47/6803 , A61K47/6831 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6879 , A61K47/6889 , C07K16/2863 , C07K16/30 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/72 , C07K2317/73 , C07K2317/92
摘要： The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
公开(公告)号：US11884746B2
公开(公告)日：2024-01-30
申请号：US17240278
申请日：2021-04-26
CPC分类号： C07K7/06 , A61K47/65 , A61K47/6803 , A61K47/6835 , A61K47/6889 , A61K49/0056 , C07K7/08 , C07K16/00 , C07K16/2809 , C07K16/2863 , A61K2039/505 , C07K2317/54 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/92 , C07K2319/50
摘要： The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
-
公开(公告)号：US11859010B2
公开(公告)日：2024-01-02
申请号：US17930143
申请日：2022-09-07
CPC分类号： C07K16/40 , A61P35/00 , C07K16/2809 , C07K16/2863 , C12N15/62 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/64 , C07K2317/71 , C07K2317/73
摘要： Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
-
公开(公告)号：US20230035290A1
公开(公告)日：2023-02-02
申请号：US17699846
申请日：2022-03-21
IPC分类号： C07K14/56 , C07K14/00 , C07K14/555 , A61K47/64 , A61K47/65 , C07K19/00 , C07K14/565 , C07K14/57 , C07K16/00 , G01N33/68 , C07K14/705 , C12N15/10
摘要： The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.
-
公开(公告)号：US20220296692A1
公开(公告)日：2022-09-22
申请号：US17618658
申请日：2020-06-12
发明人： Rachel Humphrey , Matthias Will , Yifah Yaron
摘要： The invention relates generally to use of a neoadjuvant combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.
-
公开(公告)号：US20220162332A1
公开(公告)日：2022-05-26
申请号：US17471804
申请日：2021-09-10
发明人： Rachel Humphrey , Lori Carman , Matthias Will , Beiyao Zheng , Kathe Balinski
摘要： The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
8.发明授权公开(公告)号：US11161906B2
公开(公告)日：2021-11-02
申请号：US14340872
申请日：2014-07-25
发明人： Henry Bernard Lowman , James William West , Sherry Lynn La Porte , Bryan Allen Irving , Daniel Robert Hostetter , Chihunt Wong
IPC分类号： C07K16/28
摘要： The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
公开(公告)号：US20210179713A1
公开(公告)日：2021-06-17
申请号：US16725587
申请日：2019-12-23
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , C07K16/30
摘要： The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
公开(公告)号：US11035859B2
公开(公告)日：2021-06-15
申请号：US16277497
申请日：2019-02-15
IPC分类号： G01N33/573 , A61K49/00 , C07K16/28 , G01N33/574 , A61K47/68
摘要： The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
-
-
-
-
-
-
-
-
-
搜索结果
137 条记录 (耗时 0.028 秒)
